Testing QRX3 for kidney failure in hospitalized patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, QRX3, for a specific type of sudden kidney failure (acute tubular necrosis) in hospitalized patients. It aims to see if the drug can help improve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be currently in the hospital.
- You have sudden kidney failure (acute renal failure).
- A kidney doctor has diagnosed you with a specific type of kidney damage called acute tubular necrosis, or tests show high sodium in your urine (a sign of this damage).
- You are willing and able to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QRX-3 to see if it can prevent or slow down kidney disease. It is for people whose kidney function is moderately low and getting worse, but not too quickly.
This trial tests whether finerenone (a medicine that helps protect the kidneys) can improve recovery from acute kidney injury (sudden kidney failure) in hospitalized patients. Participation involves taking the study drug or a placebo while in the hospital.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This early-phase study tests whether RVX000222 is safe and effective in people with end-stage kidney disease who receive hemodialysis. If you join, you’ll be carefully monitored to see how your body responds and whether it changes kidney-related health measures.
This research study tests a special fluorescent marker (a glowing dye) to help doctors better assess how well your kidneys are working. You would be hospitalized in an intensive care unit, and the study helps evaluate a new way to monitor kidney function in critically ill patients.
This trial tests the safety of a new medicine (MK-2828) in people with advanced kidney disease or on dialysis, and compares them to healthy volunteers. The goal is to understand how the drug works in the body and if it's safe for these patients.
Hear when a new Acute Renal Failure (ARF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.